KESTRA MEDICAL TECHNOLOGIES, LTD.
About KESTRA MEDICAL TECHNOLOGIES, LTD.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $59.8M
- Net income
- -$113.8M
- Total assets
- $295.7M
- Market cap
- $1.1B
- Gross margin
- 40.5%
- Operating margin
- -177.8%
- Net margin
- -190.3%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $59.8M
- Cost of revenue
- $35.6M
- Gross profit
- $24.2M
- Operating expenses
- $130.6M
- Operating income
- -$106.4M
- Income tax
- $135.0K
- Net income
- -$113.8M
- EPS (basic)
- $-5.13
- EPS (diluted)
- $-5.13
Balance sheet
- Total assets
- $295.7M
- Current assets
- $255.3M
- Total liabilities
- $90.3M
- Current liabilities
- $38.0M
- Shareholders’ equity
- $205.4M
Cash flow
- Operating cash flow
- -$77.6M
- Investing cash flow
- -$23.3M
- Financing cash flow
- $330.3M
- Net cash flow
- $229.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.1B
- EPS (diluted)
- $-5.13
- Shares outstanding
- 57.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 6, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $113.8M in FY2025.
- Gross margin of 40.5%, net margin -190.3%.
- Trading 30% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review KESTRA MEDICAL TECHNOLOGIES, LTD..
Write a review
News about KESTRA MEDICAL TECHNOLOGIES, LTD.
News & sentiment via Polygon.io
